News & Updates

Deep learning using chest radiographs identifies smokers at risk for lung cancer

12 Sep 2020

The convolutional neural network (CXR-LC) model has successfully pinpointed smokers who are at increased risk for incident lung cancer beyond Centers for Medicare & Medicaid Services (CMS) eligibility and using information commonly available in the electronic medical record (EMR), reports a study.

Deep learning using chest radiographs identifies smokers at risk for lung cancer

12 Sep 2020

SG parents share experiences of caring for children with cancer

11 Sep 2020 by

A pilot focus group study has identified several themes indicating universal and unique caregiving experiences among Singaporean parents of children with cancer and those reported in western and other Asian cultures.

SG parents share experiences of caring for children with cancer

11 Sep 2020

Calcium channel blockers may raise prostate cancer risk

11 Sep 2020

Men who use calcium channel blockers (CCBs) are at risk of developing prostate cancer, and the risk increases with the duration of CCB exposure, according to the results of a systematic review and meta-analysis.

Calcium channel blockers may raise prostate cancer risk

11 Sep 2020

T2D dampens survival in HCC patients undergoing transarterial chemoembolization

10 Sep 2020

For patients with intermediate-stage hepatocellular carcinoma (HCC) who have undergone transarterial chemoembolization (TACE), long-term survival decreases in the presence of type 2 diabetes (T2D), a study reports.

T2D dampens survival in HCC patients undergoing transarterial chemoembolization

10 Sep 2020

ANCHOR CRC: Triple therapy combo improves ORR in BRAF V600E-mutant mCRC

09 Sep 2020 by

The combination of encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) improves objective response rate (ORR) in patients with BRAF^V600E-mutant metastatic colorectal cancer (mCRC) in the first-line setting, according to the ANCHOR CRC* trial presented at ESMO GI 2020.

ANCHOR CRC: Triple therapy combo improves ORR in BRAF V600E-mutant mCRC

09 Sep 2020

eXalt3: Ensartinib trumps crizotinib in ALK+ NSCLC

08 Sep 2020 by

In patients with locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC), treatment with the ALK tyrosine kinase inhibitor ensartinib led to superior progression-free survival (PFS) compared with crizotinib, according to interim results of the phase III eXalt3* trial.

eXalt3: Ensartinib trumps crizotinib in ALK+ NSCLC

08 Sep 2020

Aspirin may accelerate cancer progression in elderly patients

08 Sep 2020

Use of aspirin in older adults with cancer may do more harm than good, exerting an adverse effect on later stages of cancer evolution, as reported in a study.

Aspirin may accelerate cancer progression in elderly patients

08 Sep 2020

INVICTUS crossover analysis boosts potential of ripretinib for GIST

08 Sep 2020 by

The novel switch-control tyrosine kinase inhibitor ripretinib delivered a clinically meaningful benefit for patients with gastrointestinal stromal tumours (GISTs) following crossover from placebo, and had a safety profile consistent with that observed in the double-blind phase, according to the results of the crossover analysis of the INVICTUS trial presented at ESMO GI 2020.

INVICTUS crossover analysis boosts potential of ripretinib for GIST

08 Sep 2020

$Inotuzumab ozogamicin a promising agent against refractory acute lymphoblastic leukaemia$

Inotuzumab ozogamicin a promising agent against refractory acute lymphoblastic leukaemia

08 Sep 2020

Inotuzumab ozogamicin (InO) provides a safe and effective treatment option for patients with relapsed/refractory acute lymphoblastic leukaemia (R/R ALL) with a high disease burden, a recent study has found.

Inotuzumab ozogamicin a promising agent against refractory acute lymphoblastic leukaemia

08 Sep 2020

EV-NID1 as potential target for HCC detection and treatment

08 Sep 2020 by

Nidogen 1-enriched extracellular vesicles (EV-NID1) have demonstrated potential as a noninvasive biomarker for early detection of hepatocellular carcinoma (HCC) and as a target for HCC treatment.

EV-NID1 as potential target for HCC detection and treatment

08 Sep 2020

News & Updates

Filter by Specialty:

Specialty:

Deep learning using chest radiographs identifies smokers at risk for lung cancer

Deep learning using chest radiographs identifies smokers at risk for lung cancer

SG parents share experiences of caring for children with cancer

SG parents share experiences of caring for children with cancer

Calcium channel blockers may raise prostate cancer risk

Calcium channel blockers may raise prostate cancer risk

T2D dampens survival in HCC patients undergoing transarterial chemoembolization

T2D dampens survival in HCC patients undergoing transarterial chemoembolization

ANCHOR CRC: Triple therapy combo improves ORR in BRAF V600E-mutant mCRC

ANCHOR CRC: Triple therapy combo improves ORR in BRAF V600E-mutant mCRC

eXalt3: Ensartinib trumps crizotinib in ALK+ NSCLC

eXalt3: Ensartinib trumps crizotinib in ALK+ NSCLC

Aspirin may accelerate cancer progression in elderly patients

Aspirin may accelerate cancer progression in elderly patients

INVICTUS crossover analysis boosts potential of ripretinib for GIST

INVICTUS crossover analysis boosts potential of ripretinib for GIST

Inotuzumab ozogamicin a promising agent against refractory acute lymphoblastic leukaemia

Inotuzumab ozogamicin a promising agent against refractory acute lymphoblastic leukaemia

EV-NID1 as potential target for HCC detection and treatment

EV-NID1 as potential target for HCC detection and treatment